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Protein–protein interactionAbro1 (Abraxas brother 1), also known as KIAA0157, is a scaffold protein that recruits various polypeptides
to assemble the BRISC (BRCC36 isopeptide) deubiquitinating enzyme (DUB) complex. The BRISC enzyme
has a Lys63-linked deubiquitinating activity and is comprised of four known subunits: MERIT40 (mediator
of Rap80 interactions and targeting 40 kDa), BRE (brain and reproductive organ-expressed), BRCC36
(BRCA1/BRCA2-containing complex, subunit 3) and Abro1. We have previously shown that Abro1 has a
cytoprotective role that involves the BRISC DUB complex acting on speciﬁc Lys63-linked polyubiquitinated
substrates. In this report we identify three members of the AP-1 (activating protein-1) family, the ATF4,
ATF5 (activating transcription factor) and JunD proteins, as speciﬁc interactors of Abro1. The function of
ATF4–Abro1 interaction was investigated under normal conditions as well as under cellular stress. Abro1 is
predominantly cytoplasmic, but during cellular stress it enters the nucleus and co-localizes with ATF4.
Furthermore, this interaction with ATF4 is necessary and essential for the cytoprotective function of Abro1
following oxidative stress. The ability of Abro1 to speciﬁcally interact with a number of transcription factors
suggests a newmechanism of regulation of the BRISC DUB complex. This regulation involves the participation
of at least three known members of the AP-1 family of transcription factors.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Our studies are focused on Abro1, which is the scaffold protein of
the BRISC deubiquitinating enzyme (DUB) complex, and its potential
regulation through speciﬁc protein–protein interactions during cellu-
lar stress. Abro1 shares 39% similarity with another protein, Abraxas,
which is a scaffold protein for the BRCA1-A (breast cancer 1) DUB
complex [1]. Both complexes share three subunits: MERIT40/NBA1,
BRE/BRCC45 and BRCC36/BRCC3, a member of the JAMM/MPN+
(JAB1/MPN/Mov34) DUB metalloproteases [2–6]. The similarity be-
tween Abro1 and Abraxas is present at the amino-terminus and this
part of the protein interacts with the common subunits. We therefore
assume that the distinct function of the BRCA1-A and BRISC com-
plexes is conferred by the unique carboxy-termini of these proteins.
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rights reserved.BRCA1-A complex to speciﬁc DNA damage foci while the function
of the Abro1 carboxy-terminus domain is unknown [1,3,7–9]. Our
previous studies have shown that this domain can interact with a
human cardiospeciﬁc transcription factor, THAP5 (thanatos associat-
ed protein 5) [10]. THAP5 is predominantly expressed in the human
heart whereas Abro1 is expressed ubiquitously, suggesting the exis-
tence of other as yet unidentiﬁed proteins that interact with the
unique carboxy-terminus of Abro1 and affect its function. Further-
more, there is a disproportional number of subunits between the bet-
ter characterized BRCA1-A complex consisting of six subunits whereas
the BRISC complex consists of only four subunits. This is in spite of the
fact that both scaffold proteins, Abro1 and Abraxas, are similar and
comparable in size [2,3].
In the present study, we used the yeast two-hybrid system to iso-
late proteins that interact with the unique carboxy-terminus of
Abro1. We screened a mouse embryonic cDNA library that provides
a broad representation of various tissue speciﬁc mRNAs. We isolated
JunD, ATF4 and ATF5 as speciﬁc interactors. These interactors are all
distinct members of the AP-1 family of transcription factors [11].
They carry a basic-leucine zipper motif at their carboxy-terminus
and our studies show this domain to interact with Abro1. We selected
ATF4 for more detailed studies since this protein is expressed ubiqui-
tously and it has previously been shown to be a stress modulator with
an important function in heart disease [12,13]. Our results clearly
show that Abro1 and ATF4 interact both in vitro as well as in vivo
and this interaction is observed predominantly in the cell nucleus.
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increases leading to a concurrent up-regulation of the ATF4–Abro1
complex. Our previous studies show that Abro1 provides cytoprotection
against oxidative stress-induced cell death [14]. We now demonstrate
that ATF4 is necessary for this function of Abro1, since reducing the
ATF4 protein level signiﬁcantly impairs its anti-apoptotic role. Finally,
our results suggest that Abro1 can be involved inmultiple speciﬁc inter-
actions with various transcription factors. These interactions can either
be tissue speciﬁc or in response to a particular stress. The potential func-
tion of these interactions could be the translocation of Abro1 scaffold
protein and the BRISC complex to various subcellular compartments
including the cell nucleus. This in turn potentially allows the BRISC
DUB complex to act on speciﬁc local Lys63-linked polyubiquitinated
substrates leading to cytoprotection.
2. Materials and methods
2.1. Yeast two-hybrid screen
The EGY 48 yeast strain with the LexA-β galactosidase reporter
construct (PSH 18–34) was used to perform a yeast two-hybrid
screen on a mouse embryonic cDNA library as previously described
[10,15,16]. The bait used was the unique carboxy-terminus sequence
of the Abro1 protein (amino acids 199–415) cloned in the pGilda vector
(Clontech) and expressed as a LexA fusion protein. Several interacting
proteins were identiﬁed in this screen, including a full-length cDNA
for JunD and partial cDNAs for ATF4 and ATF5 (a complete list of the
interactors found is summarized in Table 1). The full-length cDNAs
for ATF4 and ATF5 were isolated from the mouse embryonic cDNA li-
brary using the following speciﬁc primers: mouse ATF4 full length: Fw
5′-GCTTCGAATTCATGACCGAGATGAGCTTCCTG‐3′, Rw 5′-CACCGCTCG
AGTTACGGAACTCTCTTCTTCCCCC-3′; and mouse ATF5 full length: Fw
5′-GCTTCGAATTCATGTCACTCCTGGCGACCC-3′, Rw 5′-CACCGCTCGAGC
TAGGTGCTGCGGGTCCTC‐3′. For the bZIP constructs of ATF4, ATF5,
JunD, fosB and Maf the following primers with EcoRI and XhoI
restriction sites were used: mATF4 aa280: Fw 5′-GCTCGAATTCGACC
CACCTGGAGTTAGTTTG-3′; mATF5 aa195: Fw 5′-GCTTCGAATTCCCC
GCCCGCCCAGCCCCTTATC-3′; mJunD aa241: Fw 5′-GCTTCGAATTCCCG
GACGTGCCGAGCTTCGGC-3′; mfosB aa121: Fw 5′-CCGGAATTCGGT
GGGCCTTCAACCAGCA C-3′, Rw 5′-CTGCTCGAGTTATGGCAAATCTCTCA
CCTCGC-3′; and mMaf aa286: Fw 5′-CCGGAATTCATGTCGGTGCGCGA
GCTGAAC-3′, Rw 5′-CTGCTCGAGCTACCGTTTTCTCGGAAGCCGTTG-3′.
Primers were designed with an EcoRI site at the 5′ end and XhoI site
at the 3′ end. PCR products were digested and cloned in frame into
the prey pJG4-5 vector as previously described [15]. The presence and
stability of the recombinant proteins in yeast cells was monitored
by Western blot analysis using LexA-antibodies (for baits) or HA-
antibodies (for preys).
2.2. Cell culture
HEK293T cells were grown in DMEM supplemented with 10% fetal
calf serum (Atlanta Biologicals), 2 mM L-glutamine, 1.5 g/l sodium bi-
carbonate, 1 mM sodium pyruvate, 50 U/ml penicillin, and 50 μg/ml
streptomycin (Invitrogen) at 37 °C and 5% CO2.Table 1
A list of Abro1199–415 interactors isolated in our yeast two-hybrid screen using a mouse
embryonic cDNA library.
Abro1199–415 interactors Accession number Number of independent
clones
ATF4 NM_009716.2 8
JunD NM_010592.4 4
BRCC36 NM_001018055 4
ATF5 NM_030693.2 2
UbC NM_019639 12.3. Interaction between Abro1 and ATF4 proteins in HEK293T cells
HEK293T cells were plated in 100 mm dishes and transfected with
8.0 μg of either EGFP-Abro11–415 plasmid or pEGFP-C1 empty vector
(Clontech) using Lipofectamine 2000 reagent according to the
manufacturer's instructions (Invitrogen). Fourteen hours after
transfection, half of the cells were treated with 20 μg/ml of
tunicamycin for 10 h and the other half were used as control
(untreated). Cell lysates were prepared in RIPA buffer (150 mM NaCl,
50 mM Tris–HCl pH 7.5, 1% NP-40, 0.25% sodium deoxycholate)
containing the protease-inhibitor cocktail (Roche). The lysates were
cleared by centrifugation for 10 min at 10,000 g, and total lysates were
collected and subjected to immunoprecipitation. Approximately
200 μg of total protein cell lysate was pre-cleared by mixing with pro-
tein G-Agarose beads (Roche) for 1 h followed by incubation with
ATF4 (Santa Cruz Biotechnology) or Abro1 (Bethyl) polyclonal anti-
bodies for 2 h at 4 °C. Protein G-Agarose beads were then added and
allowed to bind overnight at 4 °C. Immunoprecipitates were collected
by brief centrifugation for 3 min at 800 g and washed three times
with 500 μl RIPA buffer. After the ﬁnal wash, 25 μl of RIPA buffer and
25 μl of 2× SDS-PAGE sample buffer were added. All procedures were
performed at 4 °C. Samples were boiled for 5 min and resolved by
SDS-PAGE. Proteins were then electro-transferred onto a PVDF mem-
brane and probedwith either amousemonoclonal GFP (Santa Cruz Bio-
technology) or a rabbit ATF4 antibody followed by a goat anti-mouse or
Rabbit TrueBlot (eBiosciences) HRP-conjugated secondary-antibodies.
The immunocomplex was visualized using a SuperSignal West Pico
Chemiluminescent Substrate (Pierce).
2.4. Sub-cellular localization of Abro1 and ATF4 proteins
To investigate the sub-cellular localization of Abro1 protein in the
presence or absence of ATF4, the cDNA encoding the full length Abro1
protein was cloned into pEGFP-C1 vector (Clontech) and the cDNA for
the full length ATF4 protein was also cloned into the mRFP-C1 vector
(Clontech). HEK293T cells were grown on glass cover slips to 70%
conﬂuence and they were then transfected with 1 μg of EGFP-Abro1
and mRFP-ATF4 constructs using Lipofectamine 2000 Transfection
reagent. Half of the transfected cells were treated with 20 μg/ml
tunicamycin for 10 h and the other half used as control. Both control
and treated cells were washed and ﬁxed in 4% paraformaldehyde
(PFA), permeabilized with 0.2% Triton X-100 and incubated in room
temperature with DAPI (Molecular Probes) in order to stain the nu-
cleus. The cover slips were then washed and placed on microscope
slides using Fluoromount-G as the mounting solution. Slides were ob-
served using a Leica TCS SP5 II confocal laser-scanning microscope
(Leica). The expression and stability of the GFP-Abro1 and RFP-ATF4
proteins was veriﬁed by Western blot analysis using ATF4 or Abro1
speciﬁc antibodies. For subcellular fractionation, HEK293 cells were
grown to 80% conﬂuence and they were either left untreated (control),
treated with 20 μg/ml tunicamycin or 0.2 mM H2O2 for 10 h. Cells
were then collected and nuclear/cytoplasmic fractionationwas carried
out using the NE-PER Nuclear and Cytoplasmic Extraction Reagents
(THERMO Scientiﬁc) according to the manufacturer's protocol. A total
of 40 μg of protein from each corresponding fraction was resolved
by SDS-PAGE and analyzed by Western blotting using ATF4, Abro1,
β-actin and Histone H1 speciﬁc antibodies.
2.5. Regulation of Abro1 and ATF4 proteins by tunicamycin
HEK293T cells were plated in 60 mm dishes and when they
reached 90% conﬂuence they were treated with various concentra-
tions of tunicamycin (0, 2.5, 5, 10, 20 and 50 μg/ml) for 10 h. Total
cell lysates were prepared as described above and 40 μg of protein
was resolved by SDS-PAGE and analyzed by Western blotting using
ATF4 or Abro1 speciﬁc antibodies.
2151C.T. Ambivero et al. / Biochimica et Biophysica Acta 1823 (2012) 2149–21562.6. Inhibiting ATF4 protein level and Annexin V assay
HEK293T cells grown in 35 mm dishes were co-transfected with
2.0 μg pEGFP-C1 empty vector or pEGFP-Abro1 plasmid together with
siRNA speciﬁc for ATF4 (siATF4) siGENOME SMARTpool or scrambled
siRNA (siCON) (Thermo Scientiﬁc). Some of the transfected cells were
treated with 0.2 mM of H2O2 for 10 h. The percentage of apoptotic
cells in the transfected population was estimated by staining with
phycoerythrin-conjugated Annexin V at room temperature for 15 min
in 1× binding buffer followed by analysis on a FACSCalibur ﬂow
cytometer [10,14]. Cells were also used to prepare cell lysates for
Western blot analysis using ATF4 and Abro1 speciﬁc antibodies.
3. Results
3.1. Isolation and characterization of Abro1 speciﬁc interactors
We employed a yeast two-hybrid system to isolate LexA-
Abro1199–415 interactors. We used a mouse embryonic cDNA library
in order to screen as many diverse proteins as possible, including
any tissue-speciﬁc interactors. Furthermore, using a cDNA library
constructed from primary cells avoids a potential problem oftenC-CABR
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well as cell death. The bait in this screen was the LexA-Abro1199–415,
which represents the coil–coil domain as well as the unique carboxy-
terminus of Abro1 protein that is completely different from its ho-
mologue, Abraxas (Fig. 1A). The screen was performed as previously
described [10,15,16]. Approximately one million independent yeast
colonies were screened, one hundred interactors were isolated and
after further analysis several LexA-Abro1199–415 speciﬁc interactors
were identiﬁed (Table 1). One of the speciﬁc interactors was a cDNA
encoding the full length JunD protein, while two other cDNAs repre-
sented partial polypeptides of ATF4 (amino acids 21–349) and ATF5
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ATF4, ATF5 and JunD are the only members of the large AP-1 family
of proteins that were isolated in our screen [11]. They are distinctmem-
bers but they all carry a similar bZIP domain at their carboxy-terminus
(Fig. 1D). To investigate the speciﬁcity of the interaction between these
three proteins and LexA-Abro1199–415, as well as to investigate if the
bZIP domain is involved in this speciﬁc interaction, we chose two
other members of the AP-1 family as controls, namely fosB and Maf
[17]. ATF4, ATF5 and JunD share 59% similarity at the bZIP domain,
whereas fosB and Maf are only 33% similar (Fig. 1D) [18]. The bZIP
domain of ATF4, ATF5 and JunD clearly interacted with the unique
carboxy-terminus of Abro1 equally well or even stronger than the
full-length proteins (Fig. 1B). As predicted there was no detectable in-
teraction between LexA-Abro1199–415, and the bZIP domain of either
fosB or Maf (Fig. 1B).
3.2. Interaction of Abro1 with ATF4 in mammalian cells during stress
We focused our studies on ATF4 because this protein, like Abro1, is
expressed ubiquitously, it is known to be involved in generalized
stress response and participates in cardiovascular disease [19]. To
investigate whether Abro1 can interact with ATF4 in vivo, in the pres-
ence or absence of cellular stress, HEK293T cellswere transfectedwith a
construct encoding full-length Abro1 fused to GFP (GFP-Abro1) or
empty pEGFP-C1 vector. Tunicamycin was used to induce ER stress
and 24 h after transfection total cell lysates were collected and a GFP
antibody was used to precipitate the GFP-Abro1 protein. The presence
of any ATF4 protein in the complex was monitored by Western blot
analysis using an ATF4-speciﬁc polyclonal antibody. Fig. 2A shows that
endogenous ATF4 interacts with GFP-Abro1 in HEK293T cells under
normal conditions as well as during ER stress. After tunicamycin treat-
ment, another form of the ATF4 polypeptide with a higher molecular
weight also appears to associate with Abro1 [20]. In addition, we
performed the reverse experiment using the ATF4 antibody to precipi-
tate endogenous ATF4 and any associated GFP-Abro1 protein. Fig. 2B
clearly shows that endogenous ATF4 interacts with the GFP-Abro1 pro-
tein. There was not any detectable interaction when GFP protein was
expressed alone (Fig. 2A and B).
3.3. Subcellular localization of Abro1 and ATF4 proteins during stress
Abro1 is predominantly a cytoplasmic protein [3,4] while ATF4 is
found both in the nucleus and the cytoplasm [21]. To better under-
stand the biological role of the ATF4–Abro1 interaction, HEK293T
cells were co-transfected with GFP-Abro1 (amino acids 1–415) and
mRFP-ATF4 (amino acids 1–349). Using a Leica TCS SP5 II confocal
laser-scanning microscope we observed that in the absence of stress,
GFP-Abro1 was predominantly in the cytoplasm whereas mRFP-ATF4
was in the cell nucleus (Fig. 2C, top panel). When transfected cells
were treated with tunicamycin, some of the GFP-Abro1 protein
translocated to the nucleus where it co-localized with the mRFP-
ATF4 protein (Fig. 2C, bottom panel). In cells co-transfected with
GFP-Abro1 and empty mRFP, the GFP-Abro1 protein remained in
the cytoplasm after tunicamycin treatment (results not shown). To
quantify these results, a total of 300 co-transfected cells were counted
between 15 ﬁelds of view for each control or following tunicamycin
treatment. The average of co-transfected cells with GFP-Abro1 in
the cytoplasm was 60%, which decreased to 28% in cells treated
with tunicamycin. Cells with GFP-Abro1 in the nucleus increased
from 40% in the control to 72% in tunicamycin treated cells.
To verify that the results are not due to the overexpression of
these two GFP/RFP-fusion polypeptides, we investigated the potential
translocation and co-localization of endogenous Abro1 and ATF4 pro-
teins. For this experiment, untransfected cells were treated with
tunicamycin or H2O2 to induce cellular stress. The cytoplasmic andnuclear fractions were isolated and analyzed by SDS-PAGE followed
by Western blot. Fig. 2E shows that there was a small amount of
Abro1 protein in the cell nucleus of control untreated cells. This
level of nuclear Abro1 protein increased in cells treated with
tunicamycin or H2O2. ATF4 was almost exclusively present in the
cell nucleus; there was an increase in the ATF4 after oxidative stress
but it was not as signiﬁcant as the one following tunicamycin treat-
ment. Furthermore, ATF4 protein had slightly different mobility in
cells treated with H2O2 versus tunicamycin. These results suggest
the possibility that different mechanisms are involved in regulating
ATF4 in cells exposed to H2O2 and in cells treated with tunicamycin.
3.4. Regulation of ATF4 and Abro1 protein levels by tunicamycin
Translocation of Abro1 to the nucleus seems to occurs when ATF4
protein is overexpressed and at the same time cellular stress is in-
duced. Therefore we investigated whether the endogenous level of
ATF4 or Abro1 is regulated in cells treated with various concentra-
tions of tunicamycin. Fig. 3A shows a progressive and signiﬁcant increase
in the ATF4 protein level in cells treated with various concentrations
of tunicamycin. In contrast to ATF4, Abro1 protein level remained the
same and was not regulated by tunicamycin (Fig. 3B).
3.5. Abro1 induced cytoprotection requires the presence of ATF4 protein
Abro1 has been previously shown to have a cytoprotective role
following oxidative stress [14]. To investigate if ATF4 is involved in
this process we transfected cells with GFP-Abro1 in the presence of
ATF4 siRNA or scrambled control siRNA. Under normal conditions the
basal level of apoptosis in cells transfected with GFP-vector alone was
12.5% versus 4% in cells transfected with GFP-Abro1 (Fig. 4A). When
the cells were treated with H2O2, 71% of the cells transfected with
GFP-vector alone were apoptotic compared to 44% of cells transfected
with GFP-Abro1. Inhibiting the ATF4 protein level using siATF4 signiﬁ-
cantly reduced the Abro1 cytoprotective ability and the number of apo-
ptotic cells increased from 44% to 64% (Fig. 4A). These results clearly
demonstrate that ATF4 is necessary and essential for the cytoprotective
function of Abro1 following oxidative stress. Fig. 4B shows the ATF4
protein levels under the various conditions as well as the effect of
siATF4. Furthermore, induction of apoptosis by H2O2 in HEK293T cells
does not affect the endogenous protein levels of Abro1 (Fig. 4C) and
ATF4 (results not shown).
4. Discussion
Ubiquitination is a post-translational modiﬁcation discovered in
the 1980s that has gained a lot of attention for its biological signiﬁ-
cance and its potential role in the development of human disease
(for a recent review see [22]). The modiﬁcation is through the addi-
tion of ubiquitin, a small 76 amino-acid protein of about 8.5 kDa in
size. There are a total of eight different polyubiquitin linkages, and
depending on the lysine used on the ubiquitin for attachment, the
number of ubiquitins in a chain or type of chain made, it can bestow a
different fate to the substrate protein [23]. Ubiquitination is involved
in diverse processes such as protein degradation, cell-cycle progression,
receptor transport, immune-response and viral infection [24,25]. The
most common and better-understood form of polyubiquitination in-
volves the Lys48-linked chain. Substrates that are Lys48-linked are
known to be targeted for degradation by the 26S proteasome [23].
Another form of ubiquitination is Lys63-linked, which has a non-
proteolytic role but regulates a protein's function, its subcellular local-
ization or protein–protein interaction in response to cytoplasmic or
nuclear cues [26]. Ubiquitination can be reversed by deubiquitination,
which is mediated by DUBs. There are over 100 putative DUBs identi-
ﬁed in mammalian cells, subdivided into ﬁve-distinct families [27,28].
As with ubiquitination, deubiquitination is also highly regulated, it has
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cytoplasmic and nuclear markers respectively. *, pb0.05 versus cytoplasmic control.
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lead to many human diseases [25,27,28].
We have recently uncovered an important role for Lys63-
ubiquitination as a cytoprotective mechanism in the heart [14]. Thismechanism is mediated by the BRISC DUB complex, which contains
a member of the JAMM/MPN+family of DUBs, BRCC36. Another com-
plex that employs this JAMM/MPN+DUB is BRCA1-A. The BRCA1-A
complex has been extensively studied and is found in the nucleus
β-actin
ATF4
0 2.5 5 10 20 50 µg/ml
[tunicamycin]
1 2 3 4 5 6
β-actin
Abro1
0 2.5 5 10 20 50 µg/ml
[tunicamycin]
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Fig. 3. Regulation of ATF4 and Abro1 protein levels by tunicamycin. HEK293T cells were treated with various concentrations of tunicamycin. Total cell lysates were collected and
analyzed by SDS-PAGE and Western blotting using ATF4 (A) or Abro1 (B) speciﬁc antibodies. β-actin was used to verify equal loading of proteins in each lane. Lower panels
show ATF4/β-actin or Abro1/β-actin ratio calculated after densitometry analysis.
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stranded DNA damage repair [1,2,9]. Unlike the BRCA1-A complex,
very little is known about the normal function of the BRISC complex
or its role in cellular stress. Both complexes rely on similar scaffold pro-
teins, Abro1 and Abraxas, to recruit the various polypeptides that make
up the complex. The similarity of these two scaffold proteins is restrictedsiCON + + - - + + - -
siATF4 - - + + - - + +
H2O2 - - - - + + + +
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Fig. 4. ATF4 is required for Abro1-mediated cytoprotection during oxidative stress. HEK293
with control siRNA (siCON) or ATF speciﬁc siRNA (siATF4). Half of the cells were treated with
the population was monitored by Annexin V staining and FACS. (B) Western blot analysis of
after densitometry analysis. β-actin was used to verify equal loading of proteins in each lan
analysis for the endogenous level of Abro1 as well as GFP-Abro1 proteins in the samples usto the amino-terminus of the proteins, whereas their carboxy-terminus
is quite distinct. The BRCA1-A complex consists of the following polypep-
tides: RAP80, BRE, MERIT40, Abraxas, BRCC36 as well as the BRCA1–
BARD1 heterodimer. The BRISC complex is made up of four subunit
polypeptides: BRE, MERIT40, BRCC36 and Abro1. Three of these sub-
units (BRE, BRCC36 and MERIT40) are common in both complexessi
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Abraxas. The unique carboxy-terminus of Abraxas binds to RAP80 and
the BRCA1–BARD1 heterodimer, where the interaction is regulated by
phosphorylation [1,3]. RAP80 allows the complex to interact with
ubiquitinated histones in DNA damage foci, while BRCA1–BARD1 inter-
action helps localize the complex [8,29]. Abro1 has its own unique
carboxy-terminus and our recent studies have identiﬁed this domain
to interact with the human zinc ﬁnger protein THAP5 [10]. THAP5
expression is highly restricted to the heart and brain, and furthermore
it has no mouse or rat homologue [10]. Therefore, we assumed that,
besides THAP5, there might be other protein(s) that could interact
with Abro1 to modulate its activity or its subcellular localization. We
used a yeast two-hybrid screen to isolate and characterize Abro1 spe-
ciﬁc interactors from a mouse embryonic cDNA library. From hundreds
of potential interactors, we narrowed down our search to only a few
true protein–protein interactors. These included the JunD, ATF4 and
ATF5 proteins that are members of the AP-1 family of transcription
factors as well as the BRCC36, a known component of the BRISC com-
plex. JunD, ATF4 and ATF5 proteins are known to form homo- and
heterodimers that bind to speciﬁc DNA sites to regulate the transcrip-
tion of target genes [11].
We focused our studies on the ATF4–Abro1 interaction because
this transcription factor is expressed ubiquitously (similarly to Abro1),
it is known to be involved in cellular stress and to potentially play a
role in the development and progression of heart disease [12,13]. The
interaction of ATF4 with Abro1 was veriﬁed in yeast as well as in mam-
malian cells. The carboxy-terminus of ATF4 was shown to be responsi-
ble for the interaction with Abro1. This domain is known to carry the
bZIPmotif that is involved in protein–protein and protein–DNA interac-
tions [30]. Furthermore, this motif is similar in JunD and ATF5 proteins
that were also isolated in our screen. We veriﬁed the speciﬁcity of this
interaction by using two other members of the AP-1 family (fosB and
Maf) that have limited similarity at their bZIP motif with that of ATF4,
ATF5 and JunD, and because of this they were unable to interact with
Abro1. To investigate the biological signiﬁcance of the Abro1–ATF4 in-
teraction in normal cells and during cellular stress, cells were treated
with tunicamycin (an ER stressor) and the subcellular localization
of these two proteins was observed. Under normal conditions Abro1
is predominantly cytoplasmic and ATF4 is mostly nuclear but in the
presence of tunicamycin Abro1 is translocated into the nucleus where
it co-localized with ATF4. Since the translocation of Abro1 occurred
when ATF4 was overexpressed and stress was applied, we investigated
whether the endogenous ATF4 protein level might be regulated byBRCA1-A complex
Nuclear C
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RAP80
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Fig. 5. Schematic diagram showing the current composition of the BRISC and BRCA1-A DUB c
BRE, MERIT40) that compose the catalytic core. BRCA1-A complex contains two unique pro
Our work also identiﬁed four unique proteins (THAP5, ATF4, ATF5 or JunD), three of which
cell nucleus under conditions of cellular stress.tunicamycin. The ATF4 protein level was found to substantially increase
and be directly proportional to the concentration of tunicamycin used.
Abro1, on the other hand, did not respond to the tunicamycin treatment
and its protein level remained unchanged. Furthermore, tunicamycin
treatment not only increased the ATF4 protein level but also its
post-translational modiﬁcation. At higher tunicamycin concentrations
various forms of ATF4 with higher molecular weight appeared. We as-
sume that these represent polyubiquitinated forms of the polypeptide
since it is known that ATF4 is ubiquitinated and degraded by the
proteasome [31,32]. The biological relevance of the ATF4–Abro1 inter-
action was further investigated using a previously described assay
where overexpression of Abro1 protects cells from apoptosis induced
by oxidative stress [14]. Oxidative stress also increased the amount of
nuclear Abro1 protein. In this assay, the cytoprotective effect of Abro1
was dramatically reduced when the ATF4 protein level was inhibited
by siRNA. The interaction of Abro1 with ATF4, as well as ATF5 and
JunD, suggests that various nuclear proteins can bind to this scaffold
protein in the nucleus. These proteins could act as a “driver” for the
Abro1polypeptide in a similarmanner to the BRCA1–BARD1 interaction
with Abraxas to direct the BRCA1-A complex to the DNA damage foci
[8]. In addition, we cannot exclude the possibility that the interaction
of ATF4, ATF5 and JunD with Abro1 can also modulate the DUB activity
of the BRISC complex. Based on our data, aswell as previously published
work, we were able to assign three discernible functional domains
to the BRISC and BRCA1-A complexes: (a) the scaffold domain, repre-
sented by Abro1 and Abraxas; (b) the catalytic domain which in-
cludes the common polypeptides BRCC36, MERIT40 and BRE; and
(c) the “driver” domain which in BRCA1-A includes the BRCA1–
BARD1 heterodimer and RAP80, and in BRISC it can include one
of the following four polypeptides: ATF4, ATF5, JunD and THAP5
(Fig. 5). The presence of several “driver” proteins that could interact
with Abro1 at any time suggests that this process could be further
regulated. The identity of the “driver” proteins that interact with
Abro1 could be determined by the particular tissue/cell line or the
type and severity of the cellular stress. In addition, we have previous-
ly shown that the translocation of Abro1 to the cell nucleus by THAP5
leads to the deubiquitination of speciﬁc substrates [14]. Our results
suggest that either Abro1 translocation carries the complete BRISC
complex to the nucleus or the complex assembles soon after nuclear
localization of Abro1. It will be important to identify the Lys63-
linked polyubiquitinated substrates of BRISC and to investigate how
their deubiquitination results in cytoprotection against oxidative
stress-induced cell death.BRISC complex
ytoplasmic/Nuclear
0
Abro1
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omplexes. Both BRISC and BRCA1-A complexes share three common subunits (BRCC36,
teins, RAP80 and the BRCA1–BARD1 heterodimer, that are used to target the complex.
are members of the AP-1 family, which can be used to target the BRISC complex to the
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